2Thompson CA. FDA Approves oral vasopressin antagonist [J]. Am J Health Syst Pharm, 2009,66 (13) : 1 154.
3Otsuka America Pharmaceutical. inc. SAMSCA^TM(tolvaptan) [D]. Otsuka America Pharmaceutical Co., Ltd, 2009: 1-6.
4Ghali JK, Hamad B, Yasothan U, et al. Tolvaptan[J]. Nat Drug Discov, 2009,8 (8) : 611.
5Shoaf SE, Wang Z, Bricmoont P, et al.Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects[J]. J Clin Pharmacolo, 2007, 47 (12):1 498.
6Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia[J]. NEngl JMed, 2006,355(20) : 2 099.
7Miyazaki T, Fujiki H, Yamamura Y, et al. Tolvaptan, an orally active vasopressin V (2)-receptor antagonist-pharmacology and clinical trials[J]. Cardiovasc Drug Rev, 2007,25(1) : 1.
8Cleland JG, Coletta AP, Abdellah AT, et al. Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty[J]. Eur JHeart Fail, 2007,9( 1 ) : 92.
9Pang PS, Konstam MA, Krasa HB, et al. Effects of tolva- ptan on dyspnoea relief from the EVEREST trials[J]. Eur Hart J, 2009,30(18) : 2 233.
10Josiassen RC, Goldman M, Jessani M, et al. Doubleblind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia[J]. Biol Psychiatry, 2008,64( 12):1 097.
4Gross P,Reimann D,Henschkowski J,et al.Treatment of severe hyponatremia:conventional and novel aspects[J]. J Am Soc Nephrol, 2001, 12(17):S10-14.
5Cleland JG, Coletta AP, Abdellah AT, et al. Clinical trials update from the American Heart Association 2006:OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty[J]. Eur J Heart Fail, 2007, 9(1):92-97.
